ArticleMolecular neurobiology2025
Serum sEV miRNAs as Biomarkers in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study.Annals of clinical and translational neurology · 2026Article
- Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct CNS demyelinating disorder that differs from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). However, diagnosing MOGAD remains challenging due to the need to clinically exclude similar conditions and the variability in assay results. While liquid biomarkers have been extensively studied in MS and NMOSD, research on biomarkers for MOGAD remains limited. This study aims to investigate serum-derived small extracellular vesicle (sEV) miRNAs as potential diagnostic and prognostic biomarkers for MOGAD, distinguishing it from MS, NMOSD, and healthy controls. A comprehensive analysis of miRNAs in serum-derived sEVs was conducted to identify differentially expressed miRNAs among the groups. Correlations between miRNA profiles and clinical parameters, including the expanded disability status scale (EDSS) score and annualized relapse rate (ARR), were examined. The diagnostic potential of miRNAs was evaluated using the area under the curve (AUC) in the receiver operating characteristics (ROC) analyses. Serum samples were obtained from 47 patients (N = 11, MOGAD; N = 12, MS; and N = 12, NMOSD) and 12 healthy controls (HCs). We identified 77 dysregulated miRNAs in MOGAD patients, compared to HCs. Each three-miRNA panel demonstrated the highest AUC values for distinguishing MOGAD from HC (1.000), MOGAD from MS (0.939), and MOGAD from NMOSD (1.000). Additionally, hsa-miR-924 exhibited the strongest correlation with the EDSS score (ρ = -0.67, p < 0.001), while hsa-miR-548i showed the strongest correlation with ARR (ρ = -0.69, p < 0.001) in MOGAD. These miRNAs are involved in various pathways, including neuronal development, immune response, synaptic function, and chromatin remodeling, highlighting their potential roles in the pathophysiology of MOGAD. Serum sEV-derived miRNAs show strong potential as biomarkers for MOGAD, offering high diagnostic accuracy and correlations with clinical parameters. These findings pave the way for improved diagnostic and therapeutic strategies in MOGAD; however, further validation in larger cohorts is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.